60 stories tagged with #peut, in publish-time order across the WeSearch catalog. Tag pages update as new stories ingest.
⌘ RSS feed for this tag → or search "Peut"
Commentaires sur Amadou Ba : « Depuis quand vendre des cartes de membre peut-il constituer un « trouble à l’ordre public »? » par Citoyen
Face aux interdictions sans fondement de la vente des cartes de membre : systématiser la saisine de la cour suprême Salam à tous Face à une véritable entreprise de tentative de sab…
Commentaires sur Amadou Ba : « Depuis quand vendre des cartes de membre peut-il constituer un « trouble à l’ordre public »? » par Babacar Niang
Face aux interdictions sans fondement de la vente des cartes de membre : systématiser la saisine de la cour suprême Salam à tous Face à une véritable entreprise de tentative de sab…
Commentaires sur Amadou Ba : « Depuis quand vendre des cartes de membre peut-il constituer un « trouble à l’ordre public »? » par Babacar Niang
Face aux interdictions sans fondement de la vente des cartes de membre : systématiser la saisine de la cour suprême Salam à tous Face à une véritable entreprise de tentative de sab…
Commentaires sur Amadou Ba : « Depuis quand vendre des cartes de membre peut-il constituer un « trouble à l’ordre public »? » par Domoda
Face aux interdictions sans fondement de la vente des cartes de membre : systématiser la saisine de la cour suprême Salam à tous Face à une véritable entreprise de tentative de sab…
"Il faut aider pour préserver ce que l'on peut encore préserver", un agriculteur de Charente-Maritime part en Gironde
Alors que le feu continue de progresser en Gironde et dans les Landes, certains agriculteurs comme Patrice Rault n'hésitent pas à franchir le pas et à partir donner un coup de main…
Unicycive Therapeutics: Two CRLs, One Fixable Problem
Unicycive Therapeutics (UNCY) is rated as a speculative Buy with a scenario-weighted $10 price target, implying ~75% upside.…
Form 4 Vyne Therapeutics Inc For: 24 July
Form 4 Vyne Therapeutics Inc For: 24 July
Cathie Wood’s ARK sells Figma stock, buys Scribe Therapeutics
Form 4 Nektar Therapeutics For: 24 July
Intellia Therapeutics CFO sells $91,248 in stock
Form 4 Intellia Therapeutics Inc For: 24 July
Form 4 Nektar Therapeutics For: 24 July
NEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its Shareholders - Morningstar
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.…
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP) - Morningstar
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.…
Form 4 CytoMed Therapeutics Ltd For: 24 July
Form 13D/A CytoMed Therapeutics Ltd For: 24 July
Axsome Therapeutics (AXSM) Stock is Attractive on the Back of its Key Drug
Attovia Therapeutics Begins IPO Effort On Promising Early Trials
Attovia Therapeutics eyes a U.S. IPO to fund ATTO-1310 and its immune disease pipeline. Read the full analysis here.…
Form 4 Structure Therapeutics Inc ADR For: 24 July
Halozyme Therapeutics stock hits all-time high at 82.42 USD
Form 4 United Therapeutics Corporation For: 24 July
Form 4 United Therapeutics Corporation For: 24 July
Form 4 United Therapeutics Corporation For: 24 July
Form 4 United Therapeutics Corporation For: 24 July
Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call Transcript
Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call July 23, 2026 4:30 PM EDTCompany ParticipantsDave Gancarz - Chief Business & Strategy...…
Form 4 Keenova Therapeutics plc For: 23 July
Scribe Therapeutics prices IPO at $15 per share on Nasdaq
Scribe Therapeutics prices IPO at $15, to raise $128.7M
Form 4 OUTLOOK THERAPEUTICS INC For: 23 July
Scribe Therapeutics IPO expected to price at top of range - Bloomberg
Crispr Therapeutics: A Catalyst-Rich 12 Months Ahead
CRISPR Therapeutics offers a diversified gene-editing pipeline, with CASGEVY as its lead asset and multiple upcoming catalysts. See why I rate CRSP stock a Buy.…
Kymera Therapeutics director Bruce Booth sells $44m in shares
Kymera Therapeutics director Bruce Booth sells $34.8m in shares
Form 4 Kymera Therapeutics Inc For: 25 June
Form 4 Kymera Therapeutics Inc For: 25 June
Coiled Therapeutics establishes medical advisory board
MLB to question Dodgers doctor over report he supported Conor McGregor therapeutic PED use
Major League Baseball is planning to question Dr. Neal ElAttrache, the executive director of medical services for the Dodgers as well as the Rams, following a report from The New Y…
Apogee Therapeutics, Inc. (APGE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Apogee Therapeutics, Inc. (APGE) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 10, 2026 9:20 AM EDTCompany ParticipantsJane Pritchett...…
Why 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188%
Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Capricor Therapeutics, Inc. (CAPR) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 10, 2026 10:00 AM EDTCompany ParticipantsLinda Marbán -...…
Sionna Therapeutics, Inc. (SION) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Sionna Therapeutics, Inc. (SION) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 10, 2026 10:00 AM EDTCompany ParticipantsMichael Cloonan -...…
Heron Therapeutics In A Tough Spot After Cinvanti Court Loss (Rating Downgrade)
Heron Therapeutics hit as court invalidates key Cinvanti patents; Zynrelef can’t offset losses.…
Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control - Morningstar
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.…
4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies Global Healthcare Conference 2026 Transcript
4D Molecular Therapeutics, Inc. (FDMT) Jefferies Global Healthcare Conference 2026 June 3, 2026 3:10 PM EDTCompany ParticipantsDavid Kirn - Co-Founder,...…
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Tenaya Therapeutics, Inc. (TNYA) Jefferies Global Healthcare Conference 2026 June 4, 2026 3:10 PM EDTCompany ParticipantsFaraz Ali - CEO, Interim Principal...…
Denali Therapeutics Inc. (DNLI) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Denali Therapeutics Inc. (DNLI) Jefferies Global Healthcare Conference 2026 June 4, 2026 8:45 AM EDTCompany ParticipantsRyan Watts - Co-Founder, President,...…
CRISPR Therapeutics AG (CRSP) Presents at Jefferies Global Healthcare Conference 2026 Transcript
CRISPR Therapeutics AG (CRSP) Jefferies Global Healthcare Conference 2026 June 3, 2026 9:55 AM EDTCompany ParticipantsSamarth Kulkarni - CEO &...…
Spyre Therapeutics CFO Scott Burrows sells $532,936 in stock
Spyre Therapeutics CMO Sheldon Sloan sells $624,975 in stock
United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
United Therapeutics Corporation (UTHR) Jefferies Global Healthcare Conference 2026 June 3, 2026 12:45 PM EDTCompany ParticipantsJames Edgemond - CFO &...…
The Prognosis For Palvella Therapeutics
Palvella Therapeutics stock has surged, driven by strong results for its microcystic lymphatic malformations treatment. Read more on PVLA stock here.…
Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in Myelofibrosis Transcript
Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in Myelofibrosis June 2, 2026 2:00 PM EDTCompany...…
CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential
Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCM Transcript
Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCM June 3, 2026 8:00 AM EDTCompany...…
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.
Eli Lilly signs $1.9B gene-editing deal with Ascidian Therapeutics
Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCM - Slideshow
2026-06-03. The following slide deck was published by Tenaya Therapeutics, Inc.…
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies - Morningstar
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.…
Genetically modified hookworms produce and deliver therapeutics
Hookworms, intestinal parasites that infect hundreds of millions of people in under-resourced tropical regions around the globe, have evolved to survive inside the human gut for ye…